0001493152-23-014890.txt : 20230501
0001493152-23-014890.hdr.sgml : 20230501
20230501104554
ACCESSION NUMBER: 0001493152-23-014890
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230428
FILED AS OF DATE: 20230501
DATE AS OF CHANGE: 20230501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Catelani Michael
CENTRAL INDEX KEY: 0001689394
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37492
FILM NUMBER: 23871153
MAIL ADDRESS:
STREET 1: 12100 WILSHIRE BOULEVARD
STREET 2: SUITE 1275
CITY: LOS ANGELES
STATE: CA
ZIP: 90025
FORMER NAME:
FORMER CONFORMED NAME: Catelini Michael
DATE OF NAME CHANGE: 20161104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Anixa Biosciences Inc
CENTRAL INDEX KEY: 0000715446
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 112622630
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1031
BUSINESS ADDRESS:
STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250
CITY: SAN JOSE
STATE: CA
ZIP: 95118
BUSINESS PHONE: 408-708-9808
MAIL ADDRESS:
STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250
CITY: SAN JOSE
STATE: CA
ZIP: 95118
FORMER COMPANY:
FORMER CONFORMED NAME: ITUS Corp
DATE OF NAME CHANGE: 20140902
FORMER COMPANY:
FORMER CONFORMED NAME: COPYTELE INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0407
4
2023-04-28
0
0000715446
Anixa Biosciences Inc
ANIX
0001689394
Catelani Michael
C/O ANIXA BIOSCIENCES, INC.
3150 ALMADEN EXPRESSWAY, SUITE 250
SAN JOSE,
CA
95118
0
1
0
0
President, COO & CFO
0
Common Stock
2023-04-28
4
A
0
865
3.47
A
21155
D
The reporting person purchased the shares of common stock reported hereunder pursuant to the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the "Plan") which satisfies the requirements of Section 423 of the Internal Revenue Code. The reporting person's purchase of the shares of common stock is exempt from Section 16(b) under Rule 16b-3(c) and is exempt from the reporting requirements of Section 16 by virtue of Rule 16a-3(f)(1)(i)(B), however the reporting person has elected to voluntarily report the acquisition of the shares.
In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on April 28, 2023.
/s/ Michael J. Catelani
2023-05-01